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 More than 10% of the United States adult population is 
estimated to have diabetes ( 1 ), and the leading cause of 
increased mortality in patients with diabetes is enhanced 
atherosclerosis ( 2, 3 ). A common cluster of harmful changes 
to lipoprotein metabolism, including increased plasma 
VLDL and LDL cholesterol, occurs in type-2 diabetic pa-
tients and is characterized by the presence of small, dense 
LDL particles, low HDL , increased triglycerides, and post-
prandial lipemia ( 4, 5 ). Serum lipid and lipoprotein levels 
in patients who have well-controlled type-1 diabetes are 
generally not higher than those in people without diabe-
tes. However, hypertriglyceridemia and reduced HDL are 
common in poorly controlled patients, and plasma apoB100 
levels, which indicate the number of LDL particles, cor-
relate with glycemic control ( 5 ). This underscores the 
importance of diabetes-induced changes in lipoprotein com-
position and distribution as a cardiovascular disease (CVD) 
risk ( 4, 5 ), but how these relatively small changes in lipid me-
tabolism that occur in the general human population lead to 
increased diabetic complications of atherosclerosis is not 
completely understood. Current animal models for athero-
sclerosis have not been able to address this issue satisfactorily, 
as they rely on gross lipid abnormalities, such as the lack of 
LDLR or apoE which cause severe hypercholesterolemia. 
Although modest increases in atherosclerosis have been 
observed when these hypercholesterolemic mice are made 
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 Biochemical assays 
 After a 4 h fast, animals were anesthetized with 2,2,2-tribromo-
ethanol and blood was collected. Cholesterol, phospholipids, 
glucose, and free fatty acids were measured using commercial 
kits (Wako, Richmond, VA). Triglycerides were determined using 
a commercial kit (Stanbio, Boerne, TX). Plasma insulin, inter-
leukin (IL)-6, monocyte chemotactic protein (MCP)-1, and tumor 
necrosis factor (TNF)-  were assayed using magnetic bead im-
munoassay kits (Millipore, Billerica, MA) on a MAGPIX platform 
(Luminex, Austin, TX). Hepatic lipids were extracted by homog-
enization of liver tissue (  50 mg) in chloroform:methanol at 2:1 
by volume and analyzed as described ( 17 ). 
 Lipoprotein fractionation and VLDL secretion 
 Lipoprotein distribution and composition was determined 
with pooled plasma samples (100 µl) fractionated by fast protein 
liquid chromatography (FPLC) using a Superose 6 HR10/30 column 
(GE Healthcare, Piscataway, NJ). Pooled plasma (250 µl) was 
separated by sequential density ultracentrifugation into density frac-
tions ranging from d < 1.006 g/ml (VLDL) to 1.10 < d < 1.21 g/ml 
(HDL) and subjected to electrophoresis in a 4–20% denaturing 
SDS-polyacrylamide gel ( 18 ). ApoA1 and apoB contents were de-
termined by Western blot in individual plasma or VLDL fraction 
from pooled (n = 6) plasma samples following ultracentrifuga-
tion at d < 1.006 g/ml using 1:2,000 dilution of anti-mouse apoA1 
and anti-mouse apoB (Abcam, Cambridge, MA) primary anti-
bodies, respectively, and 1:10,000 dilution of HRP-conjugated 
anti rabbit IgG as secondary antibody (Cell Signaling, Danvers, 
MA). For apoE detection, anti-human apoE (EMD Millipore, 
Darmstadt, Germany) and HRP-conjugated anti-goat IgG as sec-
ondary antibody (Sigma-Aldrich, St. Louis, MO) were used. He-
patic secretion of triglyceride (TG) and cholesterol was measured 
following injection of Tyloxapol (0.7 mg/g body weight, Sigma-
Aldrich, St. Louis, MO) via tail vein of mice (n = 5 each geno-
type) after an overnight fast ( 17 ). 
 Atherosclerosis 
 At six months of age, mice were euthanized with a lethal dose 
of 2,2,2-tribromoethanol and perfused at physiological pressure 
with 4% phosphate buffered paraformaldehyde (pH 7.4). At 
least 30 serially cut sections of aortic root from each mouse were 
examined under the light microscope (8 mice per each geno-
type). Macrophages in the aortic sections were immunostained 
using anti-mouse monocyte/macrophage antibody (MOMA2) 
and Cy5 -labeled anti-rat IgG (Abcam, Cambridge, MA). 
 Lipoprotein uptake by macrophage 
 Peritoneal macrophages were isolated four days after intrap-
eritoneal injection of 0.5 ml of 4% (w/v) thioglycolate (BD Bio-
sciences). Macrophages were cultured for 48 h in Ham’s F-10 
medium supplemented with 5% fetal bovine serum, 100 units/ml 
penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 
5 mM (low) or 25 mM (high) glucose. Cells were incubated for 
4 h with 1 mg/ml of oxidized human LDL labeled with DiI (1,1’-
dioctadecyl-3,3,3 ′ ,3 ′ -tetramethyl-indocarbocyanine percholorate, 
Molecular Probes Inc.), and lipoprotein uptake was estimated as 
described ( 19 ). Freshly isolated macrophages were cultured for 
2 h to remove nonadhesive cells prior to lipid and gene expres-
sion analyses. Lipid contents were determined with Amplex Red 
Cholesterol Assay Kit (Invitrogen) and Triglyceride Fluorometric 
Assay Kit (Cayman Chemical). 
 Cholesterol effl ux assay 
 Peritoneal macrophages isolated from wild-type C57BL/6J 
mice were cultured in medium containing [ 3 H]choleresterol 
diabetic ( 6–10 ), the effect of diabetes on atherosclerosis in 
mice with more normal, physiological cholesterol levels 
has not been investigated. 
 Apolipoprotein E (apoE) is a small circulating protein 
associated predominantly with VLDL and HDL. It is a pri-
mary ligand for the LDLR, a crucial component in the 
clearance of plasma lipoproteins, a major determinant of 
plasma cholesterol and CVD risk ( 8 ). The  APOE gene is 
polymorphic in the human population, having three com-
mon isoforms: apoE2, apoE3, and apoE4. The apoE4 iso-
form is associated with higher LDL cholesterol and an 
increased risk of CVD ( 11 ). Previously we have reported 
that mice expressing human apoE4 in place of mouse 
apoE have normal plasma lipid and lipoprotein profi les 
when they are on regular chow ( 12, 13 ). We have also re-
ported that mice that carry one copy of the hLdlr allele, 
which encodes human LDLR protein (hLDLR) in place of 
mouse LDLR and expresses three times normal, have a 
40% reduction in plasma cholesterol. The HDL choles-
terol of the mice with hLDLR is below 50 mg/dl, and it is 
close to that normally seen in humans ( 14 ). Furthermore, 
mice expressing both human apoE4 and human LDLR 
(E4h mice) are highly sensitive to diet-induced dyslipidemia. 
Although they have low plasma cholesterol on regular 
chow, they develop hypercholesterolemia and atherosclero-
sis on a diet adjusted with fat and cholesterol contents mir-
roring those consumed by humans ( 14 ). In the current 
work, we show that uncontrolled diabetes induces athero-
sclerosis in these mice on a normal chow diet without the 
addition of high fat and high cholesterol. 
 To induce diabetes, we used the  Ins2 C96Y/+ “Akita” mutation, 
a genetic model of type-1 diabetes. In Akita mice, a C96Y 
amino acid substitution in the  Ins2 gene leads to improper 
folding of pro-insulin in the endoplasmic reticulum and 
causes eventual   -cell death ( 15 ). As a consequence, male 
Akita mice develop hypoinsulinemia and severe hypergly-
cemia beginning around one month of age. Here, we show 
that diabetic Akita mice expressing human apoE4 and hu-
man LDLR (E4hAkita) develop distinct foam cell lesions 
despite having plasma total cholesterol within a normal 
physiological range (  100 mg/dl). Neither hLDLR allele 
nor diabetes alone is suffi cient, but both are necessary for 
triggering atherosclerosis. 
 METHODS 
 Mice and induction of diabetes 
 Mice with a replacement of the endogenous  Apoe locus with 
the human APOE*4 (E4) allele and mice carrying the hLdlr allele 
encoding human LDLR protein were previously described 
( 12–14, 16 ).  Ins2Akita /J mice on a C57BL/6- background were 
obtained from the Jackson Laboratories (stock #003548). Our experi-
mental mice are all males designated as E4 ( Apoe 4/4 Ldlr +/+ Ins2 +/+ ), 
E4h ( Apoe 4/4 Ldlr h/+ Ins2 +/+ ), E4Akita ( Apoe 4/4 Ldlr +/+ Ins2 C96Y/+ ), and 
E4hAkita ( Apoe 4/4 Ldlr h/+ Ins2 C96Y/+ ). Mice were fed normal chow 
diet ad libitum (5.3% fat and 0.02% cholesterol. Prolab IsoPro 
RMH 3000; Agway Inc.). Animal experiments were conducted in 
conformity with the Public Health Service policy and approved 
by the Institutional Animal Care and Use Committees of the Uni-
versity of North Carolina. 
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not signifi cant (NS)]. However, total plasma cholesterol in 
the diabetic E4hAkita (102 ± 10 mg/dl) and E4Akita mice 
(92 ± 6 mg/dl) were indistinguishable ( P = 0.09 for inter-
actions between the effects of diabetes and LDLR geno-
type). Most importantly, the plasma levels of total cholesterol 
in the diabetic E4hAkita mice remained within the range 
seen in wild-type mice. 
 Separating lipoprotein classes by size-exclusion FPLC 
revealed that nondiabetic E4 mice carry the majority of 
their cholesterol in the form of HDL and that increasing 
LDLR levels in E4h mice resulted in a reduction in HDL 
cholesterol ( Fig. 1E , left panel). Diabetes did not change 
the levels of HDL cholesterol, and HDL in E4hAkita re-
mained lower than in E4Akita mice ( Fig. 1E , right panel). 
VLDL and VLDL remnants were increased in both dia-
betic groups, and this diabetes-associated increase was 
magnifi ed in the E4hAkita mice. Thus, although total 
plasma cholesterol in E4Akita and E4hAkita mice was in-
distinguishable, there was a dramatic shift in the lipopro-
tein profi le. Cholesterol in the E4Akita mice was primarily 
in HDL fractions, whereas cholesterol in the E4hAkita 
mice was primarily in VLDL and VLDL remnant fractions 
( Fig. 1E , right panel). Consequently, the ratio of non-HDL 
cholesterol to HDL cholesterol (3.05) in the E4hAkita 
mice was more than three times higher than in any of the 
other groups (0.45–0.78,  Fig. 1E , in parentheses). 
 Plasma protein levels of apoB100 were very low in all 
groups. Diabetes signifi cantly increased plasma apoB48 
levels ( Fig. 1F ). There was a decrease in plasma apoA1 in 
the mice with hLDLR, indicating a reduced number of 
HDL particles ( Fig. 1G ). Plasma apoE4 was also low in the 
mice with hLDLR independent of diabetes ( Fig. 1H ). SDS 
gel electrophoresis of plasma VLDL fraction isolated by 
ultracentrifugation confi rmed that hLDLR caused dra-
matic reduction of apoB100, apoE, and apoC ( Fig. 1I ). 
The reduction of apoE and apoC proteins likely accounts 
for the reduction in the triglyceride content in the rem-
nant particles. 
 Hepatic lipid content and VLDL secretion 
 Reduced insulin signaling is associated with increased 
VLDL secretion, and lipid availability is the primary deter-
minant of hepatic VLDL secretion ( 20, 21 ). Hepatic cho-
lesterol stores were similar among all the groups ( Fig. 2A ). 
 In contrast, diabetes signifi cantly lowered hepatic triglyc-
erides ( P = 0.04,  Fig. 2B ). The diabetes effect was more 
pronounced in E4Akita mice compared with E4 mice, and 
the liver triglyceride contents in E4hAkita mice were simi-
lar to those in E4h mice. 
 We estimated the rate of hepatic VLDL secretion by in-
jecting mice with Tyloxapol, which inhibits particle uptake 
and lipolysis, to mice fasted for at least 16 h to minimize in-
testinal contribution. TG accumulation in the plasma fol-
lowing Tyloxapol injection was similar for the fi rst 30 min 
postinjection but slowed signifi cantly in mice with hLDLR 
at 1 and 2 h in both the nondiabetic ( Fig. 2C , left panel) 
and diabetic ( Fig. 2C , right panel) state ( P < 0.001). Addi-
tionally, diabetes had a small but signifi cant TG secretion-
lowering effect ( P = 0.02). While diabetes resulted in an 
(1  Ci/ml) and 50   g/ml of acetylated LDL for 16 h. Cells were 
washed and incubated with 0.8% (v/v) mouse plasma in serum 
free medium for 2.5 h, and effl ux was calculated as counts in 
medium over counts in medium and cells ( 19 ). The ability of in-
dividual plasma to promote cholesterol effl ux was calculated by 
subtracting values obtained without plasma. 
 Gene expression 
 mRNA was purifi ed from liver, peritoneal macrophage, and 
thoracic aorta of 4- to 5-month-old mice using an Automated 
Nucleic Acid Workstation ABI 6700. Real-time PCR was per-
formed in an ABI PRISM 7700 Sequence Detector (Applied Bio-
systems).   -Actin mRNA was used for normalization. Sequences 
for primers and probes are available upon request. 
 Data analysis 
 Values are reported as mean ± SEM. Two-way ANOVA with dia-
betes (Akita) and hLDLR genotype as two factors was used for 
statistical analyses. Tukey-Kramer honestly signifi cant difference 
was used for posthoc comparisons between the groups. 
 RESULTS 
 Akita diabetic mice 
 By two months of age, E4Akita and E4hAkita mice were 
fully diabetic as judged by the elevation of their fasting 
plasma glucose compared with nondiabetic mice. Thus, 
fasting plasma glucose levels in E4Akita (516 ± 21 mg/dl) 
and E4hAkita mice (572 ± 26 mg/dl) at four to fi ve months 
of age were signifi cantly higher than in nondiabetic E4 
and E4h mice (157 ± 7 and 149 ± 11 mg/dl, respectively;  P < 
0.0001 for diabetic effect by two way ANOVA,  Fig. 1A ). 
 Plasma insulin levels fell to 36 ± 29 and 135 ± 49 pg/ml in 
diabetic E4Akita and E4hAkita mice, compared with 821 ± 262 
and 689 ± 202 pg/ml in nondiabetic E4 and E4h mice, re-
spectively ( Fig. 1B ). There was no signifi cant effect of LDLR 
genotype on either fasting plasma glucose or insulin. 
 Mice were maintained on regular chow without any in-
tervention. Despite a 2-fold increase in food intake, dia-
betic mice had a reduced body weight compared with 
nondiabetic mice. At six months of age, E4Akita (21.12 ± 
4.09 g) and E4hAkita (21.52 ± 1.05 g) mice weighed less 
than their nondiabetic E4 (30.89 ± 2.2 g) and E4h (28.26 ± 
5.0 g) siblings. There was no effect of hLDLR genotype on 
body weight. Signs of distress in diabetic mice, such as de-
hydration, hair loss, and signifi cant weight loss, were not 
present in the experimental mice at six months of age. 
 Plasma lipids and lipoproteins 
 Plasma triglyceride levels were not affected by diabetes, 
but the possession of an hLDLR allele led to a modest but 
signifi cant reduction of plasma triglycerides ( P < 0.004, 
 Fig. 1C ). There was no effect of diabetes or LDLR geno-
type on fasting plasma free fatty acids (data not shown). In 
contrast, plasma cholesterol levels were signifi cantly in-
creased in diabetic mice compared with nondiabetic mice 
by about 40 mg/dl ( P < 0.0001,  Fig. 1D ). In nondiabetic 
mice, plasma total cholesterol was slightly lower (51 ± 4 
mg/dl) in the E4h mice than in E4 mice [66 ± 4 mg/dl, 
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E4hAkita mice secreted primarily apoB48-containing par-
ticles ( Fig. 2E , right panel). Taken together, these data 
demonstrate that during times of fasting, the livers of dia-
betic E4hAkita mice secrete an increased number of 
proatherogenic VLDL particles that are small, apoB48-
containing, triglyceride poor, and cholesterol-rich. 
 Hepatic expression of the lipid metabolism-related genes 
 To gain insight into the effects of hypoinsulinemia on 
lipid uptake and VLDL secretion in the presence or ab-
sence of hLDLR, we measured the liver expression of sev-
eral key genes for lipid metabolism ( Table 1 ).  As expected, 
the hLDLR allele led to a 5- to 6-fold higher LDLR gene 
expression, but it did not affect the expression of other 
genes signifi cantly, with the exception of scavenger recep-
tor (SR)-B1, whose expression tended to be higher in E4h 
mice than in E4 mice. Neither diabetes nor LDLR genotype 
altered the expression of the genes for apoE, lipoprotein 
lipase (LPL), or N-deacetylase/N-sulfotransferase (NDST)1, 
approximately 40% increase in cholesterol secretion ( P < 
0.01), LDLR genotype had no signifi cant effect ( Fig. 2D ). 
Together, both diabetes and hLDLR signifi cantly altered 
the ratio of TG/cholesterol in the particles accumulated 
during 2 h after Tyloxapol injection (24 ± 3, 18 ± 2, 12 ± 2, 
and 6 ± 1 for E4, E4h, E4Akita, and E4hAkita, respectively; 
 P < 0.0001 for diabetes effect,  P = 0.01 for hLDLR effect with 
no interaction). 
 To estimate the number of lipoprotein particles being 
secreted, we measured the amount of apoB in the VLDL 
(d < 1.006 mg/dl) fraction isolated from pooled plasma at 
2, 60, and 120 min posttyloxapol injection. The secretion 
of total apoB protein was similar between the nondiabetic 
E4 and E4h mice ( Fig. 2E , left panel), although relative 
ratio of apoB100/apoB48 was higher in E4-VLDL than in 
E4h-VLDL. Diabetes increased the secretion of total apoB 
by about 3-fold ( P < 0.001), particularly in apoB48 form. 
Although the amount of total apoB secreted over 2 h was 
also similar between the E4hAkita and the E4Akita mice, 
 Fig.  1. Plasma glucose, insulin, and lipoproteins. A–D: Plasma glucose (A), insulin (B), triglycerides (C), and cholesterol (D) were mea-
sured following a 4 h fast in 4–5 month old nondiabetic and diabetic E4 mice without (white bars) and with hLDL (black bars). The num-
bers of mice used in each group are shown inside bars. * P < 0.05, ** P < 0.001. E: Pooled plasma (100 µl) from nondiabetic E4 and E4h (left 
panel) and diabetic E4A and E4hA (right panel) mice was separated on a FPLC column, and fractions were analyzed for cholesterol (top) 
and triglycerides (bottom). Non-HDL to HDL ratio is shown in parentheses. Plasma was pooled from 6–8 mice of each genotype. F, G: 
ApoB48 (F), apoA1 (G), and apoE (H) in the plasma were measured by Western blot analyzed by densitometry and expressed relative to 
the mean of E4 plasma as 100. Representative bands from each genotype are shown. I: Apolipoprotein and lipid compositions of VLDL 
fraction isolated by ultracentrifugation. VLDL fractions from 175   l plasma of E4 and E4h and from 50   l plasma of E4A and E4hA were 
subjected to a SDS gel electrophoresis and stained with Coomassie Brilliant Blue. Pie charts on the right show lipid compositions of E4A-
VLDL and E4hA-VLDL. 
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 ApoB, as well as the insulin-inhibited transcription fac-
tor forkhead box protein O1 (FOXO1) and its downstream 
target microsomal triglyceride transfer protein (MTTP), 
are key players in the production of VLDL ( 22 ). However, 
expression of the genes for these proteins was not signifi -
cantly altered either by diabetes or by LDLR genotype. 
Liver expression of ATP binding cassette transporter 
(ABC)A1, a key enzyme for HDL production, was not 
altered. 
 Diabetes-induced atherosclerosis in E4hAkita mice 
 We examined the proximal aortas of mice at six months 
of age for atherosclerotic changes. Under the light micro-
scope, no sign of vascular damage or atherosclerosis was 
noted in the of nondiabetic E4 or E4h aorta ( Fig. 3A ). 
 Likewise, none of the aortas dissected from the diabetic 
E4Akita mice showed any visible signs of atherosclerosis 
( Fig. 3B ). In marked contrast, all of the eight diabetic 
E4hAkita mice analyzed in this study had atherosclerotic 
alterations in their aortic roots. The probability of all eight 
E4hA mice having lesions but none in other groups is 
<0.0001. Fatty depositions, although small, were clearly 
present within subendothelial areas of all mice ( Fig. 3C, D , 
black arrows). Foam cells were not only present on the lu-
minal surface but also were present in medial layers in two 
of the eight mice ( Fig. 3E, F , white arrows). These foam 
cells are of monocyte origin, as they reacted with MOMA2. 
No advanced plaques with necrotic core or fi brous cap for-
mation were observed. Thus, E4hAkita mice develop ath-
erosclerosis in the absence of severe hyperlipidemia. 
 Macrophage cholesterol uptake and reverse 
cholesterol transport 
 As E4hAkita mice have plasma cholesterol levels below 
150 mg/dl, we looked for factors other than plasma lipids 
that might infl uence plaque development in these mice. 
We have previously shown that increases in LDLR expres-
sion signifi cantly increase cholesterol delivery into mac-
rophages in culture ( 19 ). To examine whether diabetes 
also affects uptake of modifi ed lipoproteins in macro-
phages and, thus, foam cell and atherosclerotic plaque for-
mation in a hyperglycemic environment, we measured 
uptake of DiI-labeled oxidized-LDL in vitro using perito-
neal macrophages isolated from nondiabetic E4 and E4h 
mice. To mimic normal and hyperglycemic environments, 
macrophages were cultured in medium containing 5 mM 
glucose or 25 mM glucose for 48 h. As shown in  Fig. 4A , 
 uptake of oxidized-LDL was not affected by the glucose 
levels in the culture medium, but the E4h macrophages 
took up more oxidized-LDL than E4 macrophages in both 
conditions (hLDLR effect  P < 0.01). Thus, increased LDLR 
expression enhances lipoprotein uptake in macrophages 
at low- or high-glucose concentrations. 
 Plasma HDL is able to mediate reverse cholesterol trans-
port. We therefore measured the capacity of plasma from 
individual mice to effl ux cholesterol using cholesterol-
loaded peritoneal macrophages isolated from wild-type 
C57BL6/J mice in culture. The cholesterol effl ux was 
strongly correlated with the apoA1 concentration of the 
an enzyme responsible for sulfation of heparin sulfate pro-
teoglycans. However, diabetes was associated with a dra-
matic 6-fold increase in expression of CD36, VLDL 
receptor (VLDLR), and leptin receptor (LEPR). Diabetes 
also increased SR-A1 expression almost 2-fold. A 3-fold in-
crease in SR-B1 was observed, but only in mice without 
hLDLR (E4Akita). Conversely, expression of preprotein 
convertase serine kexin (PCSK)9, which facilitates degra-
dation of LDLR protein, and expression of fatty acid syn-
thase (FASN) were reduced signifi cantly in diabetic mice. 
Reduction in PCSK9 and FASN appears to be enhanced in 
diabetic mice with hLDLR, but the differences between 
E4Akita and E4hAkita livers were not signifi cant. Together, 
these changes refl ect that the livers in the diabetic mice 
are preferentially metabolizing lipids. 
 Fig.  2. Hepatic lipids and VLDL secretion. A, B: Liver cholesterol 
(A) and triglycerides (B) in nondiabetic and diabetic E4 (white 
bars) and E4h mice (black bars). Numbers of mice used in each 
group are shown inside bars. * P < 0.05. C, D : Hepatic secretion of 
VLDL triglycerides (C) and cholesterol (D) following injection of 
the detergent Tyloxapol via the tail vein. Triangles are nondiabetic 
mice (left panel), and squares are diabetic mice (right panel). 
Open symbols are mice without hLDLR, and fi lled symbols are 
mice with hLDLR. F: ApoB was measured by Western blot in pooled 
samples (n = 5) of VLDL (d < 1.006 g/ml density fractions) at 2, 60, 
and 120 min postinjection. 
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IL-6 and/or MCP-1 concentrations in the plasma, but no 
genotype association was detected. Liver expression of 
genes for IL-6 and MCP-1 tended to be elevated in the dia-
betic mice without the increase in macrophage number as 
judged by the expression of CD68 ( Table 1 ). 
 To determine the contribution of diabetes and hLDLR 
to vascular function, we next examined the expression of 
several atherosclerosis-modifying genes in thoracic aortas, 
with an assumption that changes in thoracic aortas would 
be refl ective of those in aortic roots ( Fig. 5 ).  Although no 
atherosclerosis was expected in thoracic aortas of 4- to 
5-month-old chow-fed mice, macrophages in diabetic aorta 
appeared to be increased, as CD68 expression in diabetic 
mice was higher than in E4 control aorta. Furthermore, 
the expression of  Spp1 (secreted phosphoprotein 1) and 
of  Mmp-12 (metalloproteinase 12), both primarily ex-
pressed in foam cells in early atherosclerosis ( 23, 24 ), was 
elevated in aortas with hLDLR. A small but signifi cant in-
crease in mRNA for the vascular cell adhesion molecule 
(VCAM)-1 was also present in mice with hLDLR ( P < 0.02), 
with no signifi cant effects of diabetes. In contrast, diabetes 
signifi cantly increased mRNA for intracellular cell adhe-
sion molecule (ICAM)-1 ( P < 0.003), MCP-1 ( P < 0.0005), 
and endothelial selectin (SELE;  P = 0.0004), with no signifi -
cant effects of hLDLR. There were no differences in the 
expression of endothelial nitric oxide synthase, glutathi-
one peroxidase, or endothelin receptor 1a (not shown). 
 These data indicate that both diabetes and hLDLR in-
crease the vascular infl ammatory environment, diabetes 
mainly through the expression of factors known to affect 
leukocyte recruitment and LDLR mainly through accumu-
lation of lipids in vascular macrophages. 
plasma sample, which we estimated using Western blots 
(R 2 = 0.64;  P < 0.002,  Fig. 4B ). Effl ux to plasma from dia-
betic mice (circles) was not different from that of nondia-
betic mice (triangles). In contrast, effl ux to plasma from 
mice with hLDLR (fi lled symbols) was approximately 75% 
that from mice without (open symbols), although the ef-
fect of hLDLR did not reach signifi cance ( P = 0.08) be-
cause one E4hAkita plasma had high effl ux as well as high 
apoA1 level. 
 Consistent with these data, cholesterol ester (CE) con-
tent in the peritoneal macrophages isolated from E4h and 
E4hA mice was signifi cantly higher than that in E4 and 
E4A mice ( P < 0.002 for hLDLR effect,  Fig. 4C ). E4hA but 
not E4h macrophages had also increased free cholesterol 
(FC). Diabetes also had affected the cellular CE content 
( P < 0.03) but not FC content. TG content was not affected 
by either diabetes or hLDLR. Macrophage expression of 
genes for CD36, ABCA1, and ABCG1 that may infl uence 
cholesterol transport was not affected by either diabetes or 
hLDLR (data not shown). 
 Taken together, these data show that apoE4 mice with 
increased LDLR expression have enhanced lipid accumu-
lation in macrophages. However, diabetes appears to have 
only a small effect on this function. 
 Vascular infl ammation and diabetes-induced 
atherosclerosis 
 The general infl ammatory state of mice as estimated by 
plasma markers of infl ammation at six months of age was 
unremarkable, as concentrations of circulating TNF-  
were below the detectable range (< 9 pg/ml) for all mice 
(data not shown). However, some mice showed elevated 
 TABLE 1. Liver expression of genes related to lipid/lipoprotein metabolism and infl ammation 
Genotype (n)  P (ANOVA)
Gene E4 E4h E4Akita E4hAkita Diabetes LDLR Interaction
LDLR 100 ± 17 (7) 618 ± 113 ( 6 )  a 125 ± 18 ( 6 )  b 523 ± 115 ( 10 )  a, c 0.72  <0.0001 0.54
APOE 100 ± 19 (13) 94 ± 17 (7) 106 ± 15 (12) 123 ± 15 (13) 0.32 0.76 0.52
APOB 100 ± 5 (11) 115 ± 10 (9) 121 ± 14 (9) 112 ± 7 (15) 0.36 0.72 0.18
VLDLR 100 ± 17 (13) 84 ± 26 (6) 691 ± 123 ( 11 )  a, b 632 ± 125 ( 13 )  a, b  <0.0001 0.71 0.83
PCSK9 100 ± 15 (11) 111 ± 24 (8) 61 ± 16 (9) 43 ± 8 (15)  0.001 0.82 0.35
FOXO1 100 ± 20 (12) 83 ± 16 (8) 135 ± 29 (9) 88 ± 014 (15) 0.37 0.15 0.52
MTTP 100 ± 8 (11) 136 ± 18 (9) 152 ± 24 (9) 111 ± 11 (15) 0.99 0.45 0.21
NDST1 100 ± 12 (13) 85 ± 17 (9) 100 ± 14 (11) 100 ± 13 (13) 0.75 0.77 0.41
CD36 100 ± 18 (13) 86 ± 19 (7) 563 ± 53 ( 11 )  a, b 585 ± 70 ( 13 )  a, b  <0.0001 0.65 0.49
SR-B1 100 ± 9 (8) 162 ± 30 (6) 288 ± 56 ( 6 )  a, b 186 ± 26 (10)  0.002 0.53  0.014 
SR-A1 100 ± 10 (8) 99 ± 23 (6) 164 ± 40 (6) 163 ± 19 (10)  0.01 0.97 0.99
ABCA1 100 ± 14 (8) 115 ± 20 (6) 76 ± 14 (6) 100 ± 16 (10) 0.24 0.25 0.81
LPL 100 ± 10 (8) 98 ± 11 (6) 109 ± 21 (6) 119 ± 12 (10) 0.28 0.78 0.64
FASN 100 ± 27 (8) 116 ± 21(6) 83 ± 16 (6) 34 ± 4 ( 10 )  a, b  0.02 0.24 0.14
LEPR 100 ± 31 (7) 100 ± 38 (6) 505 ± 178 ( 6 )  a, b 487 ± 85 ( 9 )  a, b  0.0005 0.92 0.92
CTP1a 100 ± 16 (8) 88 ± 10 (6) 120 ± 25 (6) 128 ± 19 (10) 0.13 0.92 0.60
PPARa 100 ± 16 (8) 104 ± 18 (6) 119 ± 28 (6) 133 ± 23 (10) 0.30 0.69 0.83
LOX1 100 ± 15 (7) 95 ± 16 (6) 70 ± 15 (6) 77 ± 13 (10) 0.12 0.95 0.71
CD68 100 ± 26 (12) 111 ± 24 (10) 178 ± 58 (10) 118 ± 34 (13) 0.25 0.51 0.34
MCP-1 100 ± 30 (12) 137± (10) 392 ± 195 (10) 329 ± 115 (13) 0.053 0.98 0.61
IL-6 100 ± 20 (12) 186 ± 41 (10) 486 ± 186 (10) 463 ± 182 (13)  0.02 0.82 0.69
Mice on normal chow were between four and six months of age. Data are mean ± SE of mRNA levels relative to the mean of levels in E4 mice 
as 100. Signifi cant  P values are in bold by ANOVA using diabetes (Akita) and LDLR genotype (h) as two factors.
 a   P < 0.05 by Tukey-Kramer HSD test against E4.
 b   P  < 0.05 by Tukey-Kramer HSD test against E4h.
 c   P < 0.05 by Tukey-Kramer HSD test against E4Akita.
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rate of postprandial remnants is reduced in these mice, in 
part because LDLR preferentially sequesters apoE4 on the 
surface of hepatocytes and limits apoE4 transfer onto lipo-
proteins, an essential step for apoE-mediated lipoprotein 
clearance ( 14, 25 ). Except for an expected 5-fold higher 
expression of LDLR, hLDLR does not appear to alter the 
hepatic expression of genes related to lipoprotein uptake 
and lipid metabolism. However, hLDLR alters the compo-
sition of VLDL secreted from the liver, as indicated in a 
2-fold reduction in the rate of hepatic TG secretion, with-
out alterations in the secretion of total cholesterol and 
apoB amounts. Because each VLDL particle contains a 
single molecule of apoB protein, this implies that the 
VLDL particles secreted by E4 mice with hLDLR are the 
same in number but have less TG and are therefore smaller 
than those secreted by E4 mice without hLDLR. hLDLR 
also decreased the apoB100/apoB48 ratio, which is consis-
tent with the report by Twisk et al. who demonstrated that 
LDLR regulates hepatic apoB secretion and that overex-
pression of LDLR leads to the degradation of apoB100 but 
not of apoB48 ( 21 ). Importantly, as clearance of apoB48-
containing particles from circulation is mediated by apoE, 
reduced availability of apoE4 leads to accumulation of 
remnants in plasma. 
 Uncontrolled type1 diabetes increases food intake in 
mice and stresses the remnant clearance in E4 mice, al-
though total cholesterol levels still remain within the nor-
mal physiological range of mice (  100 mg/dl). Insulin 
has a well-established role as an inhibitor of hepatic VLDL 
secretion ( 5, 20, 22 ). It also promotes degradation of apoB 
protein ( 20 ). Consistent with these observations, we fi nd 
that diabetes signifi cantly increases the secretion of 
apoB48, indicating that the number of VLDL particles se-
creted is increased. Diabetes also caused a 2-fold decrease 
in the rate of TG secretion, which could be due to reduced 
hepatic TG stores consequent to the enhanced use of lip-
ids as a source of energy. The decrease in FASN and in-
crease in CD36 and VLDLR expression, which we found in 
the liver of diabetic mice, supports this explanation. Im-
portantly, the combination of hypoinsulinemia with 
hLDLR in the E4hAkita liver causes a marked increase in 
the secretion of small cholesterol-rich, TG-poor, apoB48-
containing particles. The effi ciency of remnant clearance 
increases in a particle size-dependent manner ( 26 ). Con-
sequently, the small size of the apoB48-containing VLDL 
particles in the E4hAkita mice impedes their apoE4-de-
pendent clearance and causes an accumulation of VLDL 
remnants in plasma ( Fig. 6 ). 
 HDL-cholesterol levels in the plasma of mice with 
hLDLR are 60% normal, regardless of diabetes. This is 
consistent with a previous report that low plasma HDL 
level occurs in transgenic mice overexpressing human 
LDLR, which was postulated to be due to increased whole-
particle uptake of apoE-containing HDL by LDLR ( 27 ). In 
addition, reduced reverse cholesterol transport and in-
creased liver SR-B1 expression may also contribute to this 
reduction. Although this degree of HDL reduction is likely 
to be harmless by itself, when it is combined with a diabetes-
induced increase in VLDL remnants, the non-HDL/HDL 
 DISCUSSION 
 The E4hAkita mouse provides a novel model of diabetic 
atherosclerosis in the absence of severe hyperlipidemia, 
one in which the diabetes-induced proinflammatory 
changes in the vasculature and the hLDLR-mediated ac-
cumulation of cholesterol in macrophages synergistically 
trigger foam cell lesions, although neither alone is suffi -
cient. There are several major features that distinguish this 
model from other mouse models of atherosclerosis. First, 
none of the genetic components important for lipopro-
tein metabolism are missing in the E4hAkita mice. Instead, 
two of the most relevant genes ( Apoe and  Ldlr ) code for 
human proteins. Second, a genetic model of type-1 diabe-
tes (the Akita mutation) avoids the toxic effects of diabetes 
inducers, such as streptozotocin or alloxan. Third, no diet 
manipulation, such as high cholesterol, high fat, or high 
cholate, is necessary to induce atherosclerosis. Finally and most 
importantly, diabetes is necessary for plaques to develop. 
 Mice simultaneously expressing human apoE4 and a high 
level of hLDLR have normal non-HDL cholesterol on chow 
diet, but they are sensitive to high-fat/high-cholesterol-
induced dyslipidemia and atherosclerosis ( 14 ). The clearance 
 Fig.  3. Atherosclerotic lesions at the aortic root. At six months of 
age, mice were euthanized and perfused with 4% PFA, and 8 µm 
sections of the aortic root were cryosectioned. Sections were stained 
with Sudan IVB to highlight lipid (red) and counterstained with 
hematoxylin. Representative images of aortic root vessel walls are 
shown for E4h (A), E4A (B), and E4hA (C–G) mice. None of the 
examined mice from the E4, E4h, or E4A group but all from the 
E4hA group showed signs of fatty streaks or macrophage foam cell 
formation. Black arrows in (C) and (D) indicate fatty intimal depo-
sitions. White arrows in (E) and (F) indicate foam cell infi ltration 
in the medial layers. G: Moma2 immunostaining of fatty intimal 
depositions (red on the bright fi eld) in the neighboring section 
of (E). 
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rolling, and adhesion to the blood vessels, which contrib-
ute to the plaque initiation. However, hLDLR did not af-
fect the expression of these genes. Instead, hLDLR, but 
not diabetes, caused a small 1.5-fold increase of VCAM-1 
gene expression in the aorta. VCAM-1 plays a crucial role 
in monocyte adhesion to the endothelium and in initia-
tion of atherosclerosis in both LDLR-null and apoE-null 
mice ( 34, 35 ). The increased VCAM-1 expression in aortas 
carrying hLDLR may therefore be a factor that contributes 
to the atherosclerosis of the E4 diabetic mice. As VCAM-1 
gene expression is also increased in E4h mice with low 
VLDL, this is not likely to be secondary to the relative in-
crease of remnant particles in the E4hAkita mice. On the 
other hand, because plasma HDL levels are signifi cantly 
low in hLDLR mice regardless of diabetes, aortic VCAM-1 
expression could be related to a reduced cholesterol ef-
fl ux. Further studies are necessary to elucidate the caus-
ative relationships between the hLDLR and VCAM-1 gene 
expression. 
 Although macrophage dysfunction is associated with 
diabetes ( 36, 37 ), we fi nd that oxidized LDL uptake in cul-
tured macrophages is increased when they have the 
hLDLR allele, which is more strongly expressed than the 
mouse allele ( 19 ). ApoE4-expressing macrophages effl ux 
less cholesterol than apoE2- or apoE3-expressing mac-
rophages in culture ( 19, 38–40 ), and increased LDLR ex-
pression reduces cholesterol effl ux from macrophages in 
an apoE4-dependent manner ( 19, 38 ). Additionally, Cash 
cholesterol ratio in the E4hAkita mice dramatically in-
creases to 3.05. This is close to that observed in humans 
(  3) and very different from the 0.45 observed in wild-
type or E4 mice. HDL has a very strong protective effect on 
CVD risk in humans, and it can signifi cantly decrease the 
risk even in the presence of high LDL ( 28 ). Importantly, 
the fact that the diabetic E4Akita mice do not develop ath-
erosclerosis although their total plasma cholesterol levels 
are as high as those of E4hAkita mice, underscores the im-
portance of the types of circulating lipoproteins. However, 
having an elevated non-HDL/HDL cholesterol ratio by it-
self is unlikely to be suffi cient to account for the diabetes-
induced atherosclerosis in the E4hAkita mice. In this 
regard, Goldberg et al. reported that atherosclerosis was 
not increased in streptozotocin-induced diabetic LDLR 
null mice with apoA1-defi ciency ( 29 ) or in mice express-
ing human apoB and CETP with LPL defi ciency ( 30 ), even 
though these mice had elevated non-HDL/HDL choles-
terol ratios. Thus, some factors in addition to the plasma 
lipoprotein changes are likely to contribute to the athero-
sclerosis of E4hAkita mice. 
 CVD risk in patients with diabetes is likely to be in-
creased via several interconnected factors, including in-
fl ammation, endothelial dysfunction, and a prothrombotic 
state that result from a disturbed glucose metabolism 
( 31–33 ). Our experiments show that diabetes increases 
MCP-1, ICAM-1, and SELE gene expression 2- to 3-fold in 
the aorta. These proteins mediate leukocyte recruitment, 
 Fig.  4. Macrophage and vascular functions. A: Macrophage LDL uptake. Primary macrophages isolated 
from E4 mice (white bars) or E4h mice (black bars) were cultured in 5 mM (low) or 25 mM (high) glucose 
medium for 48 h. Macrophages were cultured with 1 µg/ml DiI-labeled human LDL (left side) or 1 µg/ml 
DiI-labeled oxidized human LDL (right side) for 4 h, and cellular fl orescence was measured to estimate LDL 
uptake. B: Cholesterol effl ux to whole plasma correlates with plasma apoA1. Peritoneal macrophages from 
wild-type mice were labeled with [ 3 H]cholesterol and incubated for 2.5 h with whole plasma (0.8%). Choles-
terol effl ux to individual plasma is expressed as proportion of labeled cholesterol moved from cells and plot-
ted against their apoA1 levels estimated by Western blot. Open triangle, E4 mice; open circle, E4h mice; fi lled 
triangle, E4A mice; fi lled circle, E4hA mice. C: Cholesterol ester (CE), free cholesterol (FC), and triglyceride 
content of peritoneal macrophage. Statistics were with ANOVA, with hLDLR and diabetes as two factors. 
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physiological range (<120 mg/dl). We also found that dia-
betes causes proinfl ammatory changes in the vasculature 
of apoE4 mice, although this change alone was not suffi -
cient to initiate atherosclerosis. While the two experiments 
differ in how type-1 diabetes is induced, the sex of the 
mice and the mode of lipid metabolism perturbation both 
clearly demonstrate that diabetes increases atherogenesis 
with relatively modest changes in lipoprotein metabolism. 
 Translation of mouse models of atherosclerosis to hu-
mans is not straightforward because there are species dif-
ferences in their lipoprotein metabolism. For example, 
E4hAkita mice secrete predominantly apoB48-containing 
lipoproteins, remnants of which are cleared by apoE-medi-
ated mechanisms. This contrasts with humans in which 
plasma non-HDL lipoproteins contain mainly apoB100 be-
cause humans lack hepatic apoB editing ( 42 ). Small rem-
nant lipoprotein particles with apoB48, unlike comparable 
particles with apoB100, cannot be cleared by the LDLR 
unless they also have apoE. The disturbances in lipopro-
tein metabolism caused by changes in LDLR levels may 
therefore be exaggerated in mice by the accumulation 
of small apoB48 remnants. Nevertheless, recent work by 
Versmissen et al. indicates that an analogous interaction 
between the level of LDLR expression and apoE4 isoform 
may be an important contributing factor in humans ( 43 ). 
Despite the differences between mouse and human lipo-
protein metabolism, changes in the lipoprotein profi les, 
macrophage physiology, and vascular infl ammation caused 
by diabetes and by increased LDLR expression in E4hAkita 
mice are likely relevant to atherogenesis in humans. Finally, 
translating our results from a severely hypoinsulinemic 
et al. ( 41 ) recently reported that macrophages with apoE4, 
when activated by oxidized LDL, exhibit higher cell stress 
than those with the other apoE isoforms, mainly through 
potentiation of endoplasmic reticulum stress signaling. 
Thus, the combination of high expression of LDLR with 
human apoE4 induces atherogenic changes in mac-
rophages. In addition, the low plasma levels of apoA1 fur-
ther reduce the removal of cholesterol from macrophages 
in mice with hLDLR. Although the resulting macrophage 
dysfunction is not suffi cient by itself to cause foam cell 
formation, it is a signifi cant factor when combined with 
the enhanced leukocyte recruitment induced by diabetes 
( Fig. 6 ). 
 The relative contribution of hyperglycemia and dyslipi-
demia to the accelerated atherosclerosis that presents in 
diabetes is not well defi ned. Previously, Renard et al. ( 8 ) 
have shown, in a virus-induced insulinitis model, that dia-
betes causes accelerated lesion initiation without apparent 
changes in the lipid/lipoprotein profi les in LDLR-null 
mice fed a cholesterol-free diet. As diabetic mice heterozy-
gous for LDLR-defi ciency have normal plasma cholesterol 
and do not develop atherosclerosis even when fed a high-
cholesterol diet, the authors suggested that moderately 
elevated basal cholesterol levels (300 mg/dl) of the LDLR-
null mice are required for diabetes to induce arterial in-
fl ammation and lesion initiation. In our apoE4 mice, in 
contrast, diabetes caused clear changes in lipoprotein me-
tabolism, including the secretion of a larger number of 
smaller VLDL particles, although homeostatic adjustments 
maintained their plasma cholesterol levels within a normal 
 Fig.  6. Alterations of vascular environment by diabetes and by 
hLDLR in mice expressing human apoE4. Arrows moving from left 
to right indicate the effects of an increase in LDLR expression as a 
result of the hLdlr allele. Arrows moving from top to bottom indi-
cate the effects of diabetes due to  Ins2 Akita/+ . Nondiabetic E4 mice in 
top left carry most of plasma cholesterol in HDL (blue circles). In-
creased LDLR reduces HDL cholesterol in E4h (top right). Diabe-
tes increases plasma glucose (black dots) and VLDL secretion 
(E4Akita, bottom left) and in E4hAkita mice (bottom right). Inter-
actions between hLDLR and apoE4 compromise the clearance of 
remnants in E4hAkita mice, leading to an accumulation of VLDL 
remnants (red circles). In the vasculature, hLDLR increases 
VCAM-1 gene expression, whereas diabetes increases expression of 
ICAM-1, SELE, and MCP-1 (upward arrows). Additionally, hLDLR 
enhances cholesterol uptake while reduces effl ux in apoE4-ex-
pressing macrophages, leading to foam cell formation only in 
E4hAkita mice. 
 Fig.  5. Aortic gene expression of genes related to macrophage 
(A) and endothelial cells (B). Thoracic aortas were dissected from 
4- to 5-month-old mice, and mRNA was isolated for gene expres-
sion analyses. Data are expressed as fold difference in log scale rela-
tive to the mean expression in E4 mice. The numbers of mice used 
are in parenthesis. Statistical signifi cance of diabetic effects and 
hLDLR effects are by two-way ANOVA. 
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model untreated with insulin to human type-1 diabetes 
treated with insulin or to hyperinsulinemic type-2 diabetes 
prevalent in humans should be done with caution. Further 
studies are necessary to determine whether mice express-
ing human apoE4 and human LDLR are also susceptible 
to atherosclerosis induced by insulin resistance and type-2 
diabetes.  
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